Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is CINACALCET HYDROCHLORIDE, with a corresponding US DMF Number 28051.
Remarkably, this DMF maintains an Active status since its submission on May 05, 2014, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of November 06, 2015, and payment made on August 21, 2015, indicating their dedication to facilitating drug approvals, Categorized as Type II